Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel Accepts FDA's Statistical Take On Micardis, Recommends Limited Use

Executive Summary

FDA's Cardiovascular and Renal Drugs Advisory Committee sided with FDA's more conservative statistical analysis of Boehringer Ingelheim's Micardis, rejecting the company's claim that telmisartan demonstrated non-inferiority to ramipril in a pivotal trial

You may also be interested in...



10,000 Re-Randomization Sequences Confirm Simponi Efficacy Results

Centocor demonstrated that an adaptive randomization technique provided comparable results to conventional randomization during pivotal trials for Simponi (golimumab)

10,000 Re-Randomization Sequences Confirm Simponi Efficacy Results

Centocor demonstrated that an adaptive randomization technique provided comparable results to conventional randomization during pivotal trials for Simponi (golimumab)

FDA, Boehringer Disagree On Non-Inferiority Margin For Micardis Prophylaxis

Agency will tell advisory committee that non-inferiority analysis should account for improvements in standard of care that change effect size.

Related Content

Topics

UsernamePublicRestriction

Register

PS051333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel